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BACKGROUND.
Since 1995, several papers have reported the
association of high CA125 serum levels with NHL.
Most of the IPI's factors, bulky disease, high tumor
burden, the presence of effusions, abdominal
involvement, B symptoms or bone marrow
involvement were found to be associated with high
CA125 levels, whereas histology was not. CA125
serum levels at diagnosis has been reported to be a
new prognostic factor. However, CA125 levels have
rarely been examined in patients with HD.
In this study, we analyzed the clinical characteristics
associated with elevated CA 125 levels at diagnosis
and examined whether abnormal CA125 serum
levels are associated with altered OS or PFS in 99
patients with HD or NHL.
STATISTICAL ANALYSES
Presenting clinical and biological features were
evaluated by Student’s T tests for their
association with serum CA125 levels. CA125
values were log transformed before analysis.
The impact of CA125 levels and others features
on OS and PFS was also evaluated by Kaplan-
Meier's analyses and compared by log-rank
test.
CONCLUSION
While CA125 serum level correlates with a number of
features associated with more aggressive disease, it does
not enhance the performance of standard prognostic
factors in the treatment of patients with NHL or HD.
PATIENTS
N of patients
Median age (range)         56.5 yrs (15.4-88.2)
Sex
Male 57
Female 42
Performance status *
0 and 1 58
2 and 3 35
B symptoms **
No 75
Yes 21
Ann Arbor clinical stage
I 21
II 21
III 12
IV 45
Histology
Indolent lymphoma 27
 - Lymphocytic lymphoma 1
 - Follicular lymphoma 15
 - Malt lymphoma 6
 - Unclassified 5
Aggressive lymphoma 51
  -Diffuse large B cell lymphoma 39
 - Mantle cell lymphoma 6
 - Anaplastic large cell lymphoma 2
 - Peripheral T cell  lymphoma 3
 - Burkitt's lymphoma 1
Hodgkin's disease 21
 - Nodular lymphocyte-predominant 3
 - Nodular scerosis 16
 - Mixed cellularity 1
 - Unclassified 1
Sites of tumor involvement
Abdominal
  No 50
  Yes 49
Mediastinal
  No 59
  Yes 40
Bone marrow
  No 71
  Yes 28
Effusion***
  No 82
  Yes 13
aa IPI
0 31
1 30
2 23
3 11
TABLE 1 : PATIENTS' CHARACTERISTICS
RESULTS.
N of patients
Performance status *
0 and 1 58 19 (33)  19.3 (4.4-38.0)
2 and 3 35 11 (31)  62.2 (8.4-3,050.0)
B symptoms **
No 75 19 (25)  13.5 (4.4-3,050.0)
Yes 21 14 (67)  62.2 (6.8-62.5)
Ann Arbor clinical stage
I 21 0 (0)  12.3 (8.4-33.9)
II 21 4 (19)  19.8 (4.4-138.1)
III 12 6 (20)  36.1 (11.2-381.6)
IV 45 24 (53)  43.7 (6.8-3,050.0)
LDH ****
Normal 47 10 (21)  16.1 (4.4-154.1)
Elevated 51 23 (45)  43.6 (8.4-3,050.0)
b2-microglobulin**
Normal 59 13 (22)  18.6 (4.4-381.6)
Elevated 37 21 (57)  49.4 (9.4-3,050.0)
CRP
< 20 mg/L 61 15 (25)  19.2 (4.4-3,050.0)
>= 20 mg/L 38 19 (50)  30.9 (8.4-1,586.0)
Hemoglobin
>=12.5 g/dL 69 17 (25)  19.3 (4.4-1,580.0)
< 12.5 g/dL 30 17 (57)  49.4 (9.3-3,050.0)
Histology
Indolent lymphoma 27 5 (19)  15.6 (6.8-1,418.0)
Aggressive lymphoma 51 23 (45)  33.9 (4.4-3,050.0)
Hodgkin's disease 21 6 (29)  19.8 (9.3-144.0)
Sites of tumor involvement
Abdominal
  No 50 9 (18)  15.6 (9.3-127.1)
  Yes 49 25 (51)  74.0 (20.3-3,050.0)
Mediastinal
  No 59 13 (22)  13.2 (12.6-3,050.0)
  Yes 40 21 (53)  36.1 (9.3-1,586.0)
Bone marrow
  No 71 18 (25)  19.8 (4.4-381.6)
  Yes 28 16 (97)  49.4 (6.8-3050.0)
Effusion***
  No 82 21 (26)  19.8 (4.4-3,050.0)
  Yes 13 12 (92) 127.1 (9.3-1,586)
aa IPI
0 31 1 (3)  15.1 (14.4-138.1)
1 30 7 (23)  19.2 (6.8-125.4)
2 23 14 (61)  43.6 (8.4-381.6)
3 11 9 (82) 121.6 (62.2-3,050.0)
N (%) of patients with 
elevated CA 125
CA 125 median value (range)
    p=0.0003
p=0.0005
p<0.0001
p<0.0001
p=0.9
p=0.0004
p<0.0001
p=0.01
p=0.0005
p=0.010
p=0.0002
p=0.0082
p=0.0027
p<0.0001
p<0.0001
    p=0.6797
p<0.0001
p=0.0022
p<0.0001
 TABLE 2: ASSOCIATION WITH CA125 LEVELS AT DIAGNOSIS
p=0.0284
p<0.0001
p<0.0001
p=0.002
p=0.018
p=0.0005
p=0.0017
        FACTOR P RR 95% CI
PROGRESSION-FREE SURVIVAL
- WHOLE GROUP
    Performance status 0.0225 2.96 1.17 – 7.51
    Aggressive NHL 0.0399 8.60 1.11 – 67.21
    b2 microglobulin level 0.0002 5.10 2.15 – 12.14
- AGGRESSIVE NHL
    Performance status 0.0265 3.29 1.15 – 9.40
    b2 microglobulin level 0.0225 3.48 1.19 – 10.18
OVERALL SURVIVAL
- WHOLE GROUP
    Performance status 0.0026 5.68 1.83 – 17.62
    Aggressive NHL 0.0300 3.62 1.14 – 11.55
    Bone marrow involvement 0.0110 4.21 1.39 – 12.77
    b2 microglobulin level 0.0002 10.45 3.05 – 35.86
- AGGRESSIVE NHL
    Performance status 0.0110 4.72 1.43 – 15.6
    b2 microglobulin 0.0050 7.79 1.85 – 32.7
TABLE 3: COX ANALYSIS FOR PROGRESSION-FREE AND OVERALL SURVIVAL
(*):available in 93 patients; (**):available in 96 patients; (***):available in 95 patients; (****):available in 98 patients.
